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Abstract  
Background & Aims: A history of high body mass index (BMI) is strongly associated with risk 
of esophageal adenocarcinoma (EAC). We investigated whether gastroesophageal reflux is 
involved in this association. 
Methods: We analyzed data from a population-based Swedish nationwide study of patients 
with a new diagnosis of EAC (n=189) or gastroesophageal junction adenocarcinoma (n= 262), 
and matched controls (n=816), from 1995 through 1997. Our analysis included data on BMI 
20 y before study inclusion; maximum adult BMI; frequency, severity and duration of 
gastroesophageal reflux symptoms; tumor features; and covariates (sex, age, smoking, 
alcohol, fruit and vegetables intake, and socio-economic status). We conducted stratified 
analyses and synergy tests, adjusting for covariates. 
Results: Odds ratios (ORs) for EAC among subjects with BMI ≥25 20 y before inclusion, 
compared with those with BMI <25, did not differ significantly, without or with adjustment 
for gastroesophageal reflux frequency (OR, 3.1; 95% confidence interval [CI], 2.2–4.4 and OR, 
3.3; 95% CI, 2.2–4.8), severity (OR, 3.3; 95% CI, 2.2–4.8), or duration (OR, 3.2; 95% CI, 2.2–
4.7). However, there were strong interactions and synergisms between BMI and 
gastroesophageal reflux categories. BMI appeared to have the largest effect on 
gastroesophageal reflux frequency (synergy index 8.9; 95% CI, 2.3–34.1 for maximum BMI 
and gastroesophageal reflux >3 times weekly).  
Conclusions: Based on a population-based study, the association between BMI and EAC does 
not appear to be affected by symptomatic gastroesophageal reflux, although BMI and reflux 
act synergistically. 
Keywords: Obesity; overweight; reflux symptoms; synergism.  
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Introduction 
Among all obesity-related cancers, esophageal adenocarcinoma (EAC) has the strongest 
known association with body mass index (BMI),1, 2 and the association is linear.3-5 There are 
several potential mechanisms behind the overall increased risk of developing cancer among 
overweight persons,6 but the particularly strong association with EAC indicates the presence 
of a more organ-specific mechanism being involved. The most obvious explanation would be 
that overweight, through an increased intra-abdominal pressure due to visceral adiposity, 
facilitates gastroesophageal reflux which in turn causes Barrett’s esophagus and EAC.7 This 
postulated carcinogenic pathway is supported by the dose-dependent association between 
BMI and gastroesophageal reflux,8, 9 and by studies showing that abdominal and visceral 
adiposity, facilitating gastroesophageal reflux, are stronger risk factors for EAC than BMI 
alone.10 Existing epidemiological studies have consistently found that, with mutual control, 
overweight and gastroesophageal reflux symptoms are independent risk factors for EAC.2-5, 
11, 12 The degree to which gastroesophageal reflux mediates the body mass-EAC association 
deserves more in-depth studies.13 We have previously studied the role of both BMI and 
gastroesophageal reflux in the etiology of EAC and gastroesophageal junctional 
adenocarcinoma (JAC) in a nationwide Swedish case-control study,3, 7 but we did not conduct 
any in-depth analyses of how various levels BMI and gastroesophageal reflux interact in the 
development of EAC. An Australian study addressed combined effects of BMI, 
gastroesophageal reflux and tobacco smoking on the risk of EAC and found that adjustment 
for gastroesophageal reflux only modestly attenuated the association between BMI and 
EAC.11 To further explore whether the strong association between BMI and EAC, we 
hypothesized that the effect of BMI is modified by gastroesophageal reflux at certain levels 
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of frequency, severity or duration.
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Methods 
Design 
The organization and design of our Swedish population-based case-control study has been 
described in detail elsewhere.7 In brief, the study base consisted of all Swedish-born 
residents aged between 40 and 80 years in 1995 through 1997. Cases were all those newly 
diagnosed with EAC or JAC during this period. All 195 hospital departments involved in the 
diagnosis or management of these patients in Sweden collaborated in the recruitment of 
patients. Controls were randomly selected from the Swedish Register of the Total Population 
and were frequency matched for age and sex of the EAC case patients. Exposure information 
was obtained through personal interviews with all study participants. The interviews were 
conducted by professional interviewers employed by Statistics Sweden. The interviewers 
were trained to treat the cases and control in equal manner. The tumor classification was 
rigorous and uniform, which allowed us to distinguish between adenocarcinomas of the 
esophagus and those of the gastroesophageal junction (tumors within 2 cm above and 3 cm 
below the junction). All histological specimens were later re-examined by one experienced 
pathologist to make the classification more uniform for study purposes.  
 
Exposure variables and covariates 
Body mass index 
BMI was calculated as the weight in kilograms divided by the square of body height in 
meters (kg/m2). Data on weight and height 20 years prior to interview as well as maximum 
adult weight was retrospectively collected during the interviews. Normal weight was defined 
as BMI <25,   overweight as 25≤BMI<30, obesity as 30≤BMI<35, and severe obesity as BMI 
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≥35. In some analyses, categories for overweight, obesity and severe obesity were combined 
into one category (“overweight/obese” – BMI ≥25). 
 
Gastroesophageal reflux symptoms  
Gastroesophageal reflux symptoms were defined as the presence of heartburn or 
regurgitation at least weekly during at least 6 months, occurring at least 5 years prior to 
interview. This definition is well in line with the current definition of gastroesophageal reflux 
disease.14 Information about frequency and duration of reflux was collected through 
interview questions with open answers and categorized prior to the initiation of the 
analyses. We devised a severity score based on 1) symptom characteristics (heartburn only = 
1 point, regurgitation only = 1 point, both heartburn and regurgitation = 1.5 points), 2) 
nightly reflux symptoms (= 2 points), and 3) frequency of symptoms, (once per week = 0 
points, 2–6 times per week = 1 point, 7–15 times per week = 2 points, and >15 times per 
week = 3 points). 
 
Covariates 
Six potential confounding variables were evaluated: sex and age, along with tobacco 
smoking, alcohol consumption, dietary intake of fruit and vegetables, and socio-economic 
status. These covariates were selected because they have been found to have confounding 
effects in previous analyses of our case-control study.3, 7, 15-17 
 
Statistical analysis  
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Unconditional logistic regression (frequency matching) was used to calculate odds ratios 
(OR) with 95 % confidence intervals (95% CI) for various aspects of body mass and reflux 
symptoms in relation to EAC and JAC. We fitted separate models of BMI in relation to the 
cancer outcomes including and not including reflux symptoms as covariate. Furthermore, 
evaluation of effect measure modification was performed using stratification to investigate if 
the association between each single exposure and EAC or JAC varied over strata of a second 
variable. This was performed both for BMI as the exposure with reflux symptoms as the 
stratification variable and for reflux symptoms stratified by BMI. Synergy index (S) was used 
to test additive interaction of the combined effect of BMI and reflux symptoms.18 Interaction 
is present if there is departure from the additivity scale S≠1. All models were adjusted for sex 
(men, women), age (in 5-year classes), tobacco smoking status (never, previous, or current 
user of any type of tobacco, as assessed 2 years prior to inclusion), alcohol consumption (0, 
1-15, 16-70, or >70 grams per week), dietary intake of fruit and vegetables (low, 
intermediate or high), and educational level (0-6 years, 7-10 years, or >10 years of formal 
education). Four controls of 820 were excluded due to missing values on the BMI variables. 
All data management and analysis was carried out by using SAS, version 9.2 (SAS Institute 
Inc., Cary, NC, USA).  
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Results 
Participants 
Included were 189 patients with EAC, 262 patients with JAC, constituting 87% and 83%, 
respectively, of all eligible incident cases that occurred within the study base. The 816 
control subjects constituted 75% of all subjects who had been originally selected. Some 
characteristics of the participants are presented in Table 1. Presence of overweight and 
reflux was highest in cases of EAC, followed by cases of JAC, and lowest in the control 
participants. Use of tobacco and alcohol was highest in JAC patients, slightly lower in cases 
of EAC, and lowest among controls. A highest attained educational level of >10 years was 
most common among control participants and least common among EAC cases (Table 1).  
 
Mutually adjusted associations 
The crude ORs were generally similar to the multivariably adjusted ORs. Therefore, only the 
adjusted ORs are presented. The associations between BMI 20 years before inclusion and 
risk of EAC were similarly strong without (OR 3.1, 95% CI 2.2-4.4) and with adjustment for 
gastroesophageal reflux frequency (OR 3.3, 95% CI 2.2-4.8), severity (OR 3.3, 95% CI 2.2-4.8) 
or duration (OR 3.2, 95% CI 2.2-4.7). The same pattern was found for maximum BMI and for 
risk of JAC, i.e. the risk estimates were not attenuated after adjustment for 
gastroesophageal reflux variables (Table 2). Similarly, when gastroesophageal reflux 
frequency, severity and duration were analyzed in relation to risk of EAC and JAC the 
adjustment for BMI variables did not attenuate the results (Table 2). When, for example, 
comparing gastroesophageal reflux severity score >4 with 0, the risk of EAC was of similar 
strength without and with adjustment for BMI 20 years before inclusion (OR 18.0, 95% CI 
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10.9-29.6 and OR 19.2, 95% CI 11.4-32.3, respectively). The analyses were repeated for more 
categories of BMI, and although hampered by low statistical precision, the patterns were 
similar to those reported above (data not shown).  
 
Stratified analyses 
Tables 3 and 4 present stratified analyses in various combinations of BMI and 
gastroesophageal reflux variables. The relative risk estimates for gastroesophageal reflux 
frequency, severity and duration were similar among participants with BMI ≥25 and <25 (20 
years before interview) (Table 3), the only exception being a lower point estimate for 
gastroesophageal reflux with a duration over 20 years among individuals with BMI ≥25 (OR 
9.3, 95% CI 3.8-23.0) than among those with BMI <25 (OR 24.4, 95% CI 10.8-55.3). When 
analyses were stratified according to the maximum BMI in adult life, point estimates for the 
highest category of each gastroesophageal reflux variable suggested higher relative risks of 
EAC and JAC among participants with maximum BMI ≥25, but the precision was poor and the 
differences were not statistically significant (Table 3). In Table 4, the BMI categories <25 and 
≥25 were compared in various levels of gastroesophageal reflux frequency, severity and 
duration. The risk estimates of EAC increased with a higher frequency and severity of 
gastroesophageal reflux in participant with BMI ≥25 compared to normal BMI, but no such 
pattern was seen for gastroesophageal reflux duration. Poor precision also limited analyses 
of the association between BMI and risk of EAC and JAC, stratified by gastroesophageal 
reflux status (Table 4), but by and large the risk gradient tended to be steeper in the strata 
with the highest gastroesophageal reflux frequency, severity and duration.  
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Synergy analysis 
There were mostly strong and statistically significant synergisms between BMI and 
gastroesophageal reflux, particularly gastroesophageal reflux frequency, in their association 
with EAC. Synergy indexes typically ranged between 2 and 4 (Table 5), but the strongest one 
(8.9, 95% CI 2.3-34.1) was between maximum adult BMI (<25 versus ≥25) and 
gastroesophageal reflux frequency dichotomized into ≤3 versus > 3 gastroesophageal reflux 
episodes per week. The synergisms tended to be somewhat weaker when JAC was the 
outcome, and none of these synergy indexes attained statistical significance.  
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Discussion 
This study did not reveal any evidence in support of the hypothesis that gastroesophageal 
reflux is a mediator of the association between BMI and risk of EAC or JAC. We found 
suggestive evidence of additive interactions and synergisms between these two exposures in 
relation to risk of these tumors, and when EAC was the outcome, the evidence of synergisms 
was convincing. 
 
Strengths of the study include the population-based design with rapid case ascertainment 
and high participation rates, thorough tumor characterization, personal interviews with all 
study participants, the detailed information about the study exposures and covariates, and 
the ability to adjust the results for confounding by other known risk factors. Among 
limitations is the risk of misclassification of the exposures, which might be different in cases 
and controls, i.e. recall bias. Separate analyses were, however, conducted also among 167 
cases of squamous cell carcinoma of the esophagus, and no associations were found 
between BMI, gastroesophageal reflux or any combinations of these two study exposures 
and risk of this cancer (data not shown). This finding might argue against strong influence of 
recall bias, since such bias would be expected in these patients as well, but recall bias can 
nevertheless not be ruled out. Finally, the statistical power was limited, particularly in sub-
group analyses, leaving a risk of chance findings.  
 
The additive effect was seemingly more pronounced for maximum BMI than BMI 20 years 
before interview. This might be due to the higher level of BMI in the former variable, or that 
the gastroesophageal reflux co-exists more often in the latter variable. There was a lack of 
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additive interaction (S=1.1) when gastroesophageal reflux duration and BMI 20 years before 
interview were analysed, i.e. when the exposures were obviously present at the same time.  
 
The association between BMI and EAC is stronger than that of any other obesity-related 
cancer.1, 2 Since BMI is a dose-dependent risk factor for gastroesophageal reflux,8, 9 and 
gastroesophageal reflux is a strong and organ-specific risk factor for EAC,7, 19 there are good 
reasons to believe that the association between BMI and EAC is mediated by 
gastroesophageal reflux. However, most previous epidemiological studies have reported a 
similar strength in the association between BMI and EAC in individuals with and without 
gastroesophageal reflux symptoms.2-5, 11, 20 A population-based case-control study from 
Australia found similar patterns regarding gastroesophageal reflux combined with BMI, but 
that study did not include analyses of how higher levels of frequency, severity or duration of 
gastroesophageal reflux symptoms influenced the results.11 The lack of evidence from 
previous research together with the present in-depth analysis of this issue argues against the 
hypothesis that the association between obesity and EAC is mediated only by 
gastroesophageal reflux. Perhaps asymptomatic gastroesophageal reflux could play a role, 
since 40% of the cases EAC do not report gastroesophageal reflux symptoms,7 while most of 
them likely have Barrett´s esophagus.21 There is, however, some empiric evidence in support 
of a high frequency of asymptomatic gastroesophageal reflux in obese individuals.4, 22 
Nevertheless, there is a need to also consider other organ-specific mechanisms that might 
explain the overweight-EAC association, e.g., a prolonged esophageal emptying,4 a divergent 
microflora,23 and an increased consumption of food in general in obese individuals might 
result in an increased esophageal exposure to carcinogenic dietary factors. 
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In conclusion, this carefully conducted population-based study found no support for the 
hypothesis that the association between BMI and EAC is importantly mediated by 
symptomatic gastroesophageal reflux. Other organ-specific mechanisms explaining why the 
association between BMI and EAC is stronger than that of any other cancer deserve 
attention.  
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Table 1. Characteristics of control participants and cases of esophageal adenocarcinoma (EAC) and 
gastroesophageal junctional adenocarcinoma (JAC). 
 
Controls  EAC  JAC 
Characteristic Number (%)  Number (%)  Number (%) 
Sex 
 
 
 
 
 Men 676 (83)            165 (87)            223 (85)           
Women 140 (17)              24 (13)              39 (15)           
Age (years) 
 
 
 
 
 <54 128 (16)              23 (12)              53 (20)           
55-59   80 (10)              15 (8)               22 (8)            
60-64 106 (13)              25 (13)              36 (14)           
65-69 139 (17)              36 (19)              48 (18)           
70-74 180 (22)              52 (28)              62 (24)           
75-79 183 (22)              38 (20)              41 (16)           
BMI 20 years before interview 
 
 
 
 
 <25 573 (70)              78 (41)            147 (56)           
≥25 243 (30)            111 (59)            115 (44)           
BMI maximum as adult 
 
 
 
 
 <25 300 (37)              32 (17)              70 (27)           
≥25 516 (63)            157 (83)            192 (73)           
Reflux  frequency (times per week) 
 
 
 
 
 <1 681 (83)              76 (40)            187 (71)           
1-3 109 (13)              72 (38)              57 (22)           
>3   26 (3)               41 (22)              18 (7)            
Reflux severity (score)  
 
 
 
 
 0 681 (83)              76 (40)            187 (71)           
1-4 101 (12)              49 (26)              48 (18)           
>4   34 (4)               64 (34)              27 (10)           
Reflux duration (years) 
 
 
 
 
 0  681 (83)              76 (40)            187 (71)           
1-20 108 (13)              73 (39)              53 (20)           
>20   27 (3)               40 (21)              22 (8)            
Tobacco smoking status 
 
 
 
 
 Never 323 (40)              57 (30)              43 (16)           
Previous 313 (38)              89 (47)            124 (47)           
Current 180 (22)              43 (23)              95 (36)           
Alcohol use (grams of ethanol per week) 
 
 
 
 
 0 131 (16)              41 (22)              34 (13)           
1-15 219 (27)              54 (29)              73 (28)           
16-70 289 (35)              51 (27)              79 (30)           
>70 177 (22)              43 (23)              76 (29)           
Intake of fruit and vegetables 
 
 
 
 
 Low  215 (26)              69 (37)              97 (37)           
Intermediate  325 (40)              69 (37)              98 (37)           
High 276 (34)              51 (27)              67 (26)           
17 
 
Educational level (years) 
 
 
 
 
 0-6 180 (22)              48 (25)              43 (16)           
7-10 317 (39)              94 (50)            126 (48)           
>10 319 (39)              47 (25)              93 (35)           
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Table 2. Risk of esophageal adenocarcinoma and junctional adenocarcinoma, expressed as odds 
ratio (OR) with 95% confidence intervals (CI) in various categories of body mass index (BMI) and 
gastroesophageal reflux symptoms with and without mutual adjustments. 
 
Esophageal 
adenocarcinoma 
 Junctional 
adenocarcinoma 
Variable OR (95% CI)  OR (95% CI) 
BMI 20 years before interview 
 
 
 ≥25 vs. <25*   3.1 (2.2-4.4)      2.0 (1.5-2.7)   
≥25 vs. <25, adjusted for reflux frequency +*   3.3 (2.2-4.8)      2.0 (1.5-2.7)   
≥25 vs. <25, adjusted for reflux severity +*   3.3 (2.2-4.8)      2.0 (1.4-2.7)   
≥25 vs. <25, adjusted for reflux duration +*   3.2 (2.2-4.7)      2.0 (1.5-2.7)   
BMI maximum as adult 
 
 
 ≥25 vs. <25   2.6 (1.7-3.9)      1.6 (1.2-2.2)   
≥25 vs. <25, adjusted for reflux frequency +*   2.6 (1.7-4.1)      1.6 (1.1-2.2)   
≥25 vs. <25, adjusted for reflux severity +*   2.6 (1.7-4.1)      1.6 (1.1-2.2)   
≥25 vs. <25, adjusted for reflux duration +*   2.7 (1.7-4.2)      1.6 (1.1-2.2)   
Reflux frequency (per week) 
 
 
 1-3 vs. <1   6.2 (4.2-9.2)      2.0 (1.3-2.9)   
1-3 vs. <1, adjusted for BMI 20 years ago +*    6.0 (4.0-9.0)      1.9 (1.3-2.8)   
1-3 vs. <1, adjusted for maximum BMI +*   6.2 (4.1-9.3)      1.9 (1.3-2.8)   
>3 vs. <1 14.4 (8.2-25.5)     2.3 (1.2-4.5)   
>3 vs. <1, adjusted for BMI 20 years ago +* 16.3 (9.0-29.5)     2.4 (1.2-4.6)   
>3 vs. <1, adjusted for maximum BMI +* 14.7 (8.2-26.2)     2.4 (1.2-4.6)   
Reflux severity (score) 
 
 
 1-4 vs. 0   4.4 (2.9-6.8)      1.8 (1.2-2.7)   
1-4 vs. 0, adjusted for BMI 20 years ago +*   4.3 (2.8-6.7)      1.8 (1.2-2.7)   
1-4 vs. 0, adjusted for maximum BMI +*   4.4 (2.9-6.9)      1.8 (1.2-2.6)   
>4 vs. 0 18.0 (10.9-29.6)    2.8 (1.6-4.9)   
>4 vs. 0, adjusted for BMI 20 years ago +* 19.2 (11.4-32.3)    2.7 (1.5-4.8)   
>4 vs. 0, adjusted for maximum BMI +* 18.1 (10.9-30.2)    2.7 (1.6-4.8)   
Reflux duration (years) 
 
 
 1-20 vs. 0    6.2 (4.2-9.3)      1.7 (1.2-2.6)   
1-20 vs. 0, adjusted for BMI 20 years ago +*   6.1 (4.0-9.1)      1.7 (1.2-2.5)   
1-20 vs. 0, adjusted for maximum BMI +*   6.1 (4.1-9.2)      1.7 (1.2-2.5)   
>20 vs. 0  14.2 (8.0-25.1)     3.4 (1.8-6.4)   
>20 vs. 0, adjusted for BMI 20 years ago +* 15.8 (8.7-28.7)     3.4 (1.8-6.5)   
>20 vs. 0, adjusted for maximum BMI +* 15.3 (8.5-27.5)     3.4 (1.8-6.5)   
 
* Adjusted for sex, age, tobacco smoking, alcohol use, intake of fruit and vegetables, and educational level. 
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Table 3. Association between gastroesophageal reflux symptoms and esophageal or junctional 
adenocarcinoma stratified by body mass index (BMI), expressed as odds ratio (OR) with 95% 
confidence intervals (CI). 
 
Esophageal 
adenocarcinoma 
 Junctional  
adenocarcinoma 
 
OR (95% CI) OR (95% CI)  OR (95% CI) OR (95% CI) 
   
 
  
 
BMI 20 years before interview 
 
BMI<25 BMI≥25  BMI<25 BMI≥25 
Reflux frequency (per week) 
  
 
  <1   1.0 (Reference)   1.0 (Reference)    1.0 (Reference)   1.0 (Reference) 
1-3   6.7 (3.6-12.3)    5.4 (3.0-9.5)      2.3 (1.4- 3.8)    1.7 (0.9-3.2)   
>3 17.6 (7.9-38.8)  17.9 (6.2-51.7)     2.0 (0.8- 4.7)    3.3 (1.0-11.0)  
Reflux severity (score) 
  
 
  0   1.0 (Reference)   1.0 (Reference)    1.0 (Reference)   1.0 (Reference) 
1-4    4.5 (2.3- 8.8)    4.1 (2.2-7.7)      2.1 (1.3- 3.6)    1.5 (0.8-3.0)   
>4 22.3 (10.9-45.8) 18.1 (7.7-42.4)     2.4 (1.1- 5.2)    3.2 (1.3-8.0)   
Reflux duration (years) 
  
 
  No    1.0 (Reference)   1.0 (Reference)    1.0 (Reference)   1.0 (Reference) 
1-20   5.8 (3.1-10.8)    6.3 (3.5-11.2)     1.7 (1.0- 2.9)    1.8 (0.9-3.4)   
>20 24.4 (10.8-55.3)   9.3 (3.8-23.0)     5.2 (2.2-12.0)    2.4 (0.8-6.6)   
   
 
  
 
BMI maximum as adult 
 
BMI<25 BMI≥25  BMI<25 BMI≥25 
Reflux frequency (per week) 
  
 
  <1   1.0 (Reference)   1.0 (Reference)    1.0 (Reference)   1.0 (Reference) 
1-3   9.3 (3.6-24.2)    5.7 (3.6-9.0)      1.7 (0.8-3.9)    2.1 (1.3-3.2)   
>3   5.8 (1.5-22.6)  19.0 (9.4-38.6)     1.3 (0.4-4.7)    3.0 (1.3-6.8)   
Reflux severity (score) 
 
   
  0   1.0 (Reference)   1.0 (Reference)    1.0 (Reference)   1.0 (Reference) 
1-4    6.1 (2.2-17.2)    4.2 (2.6-6.8)      1.8 (0.8-3.9)    1.8 (1.1-2.9)   
>4 12.7 (4.0-40.6)  20.9 (11.3-38.6)    1.3 (0.4-4.6)    3.5 (1.8-6.8)   
Reflux duration (years) 
  
 
  No    1.0 (Reference)   1.0 (Reference)    1.0 (Reference)   1.0 (Reference) 
1-20   6.2 (2.3-16.7)    6.0 (3.9-9.5)      1.5 (0.7-3.4)    1.8 (1.1-2.8)   
>20 15.0 (4.3-51.7)  17.0 (8.3-35.0)     1.9 (0.5-7.1)    4.7 (2.2-10.0)  
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Table 4. Association between body mass index (BMI) and esophageal or oesophago-gastric junctional adenocarcinoma stratified by gastroesophageal 
reflux symptoms, expressed as odds ratio (OR) with 95% confidence intervals (CI). 
 Esophageal adenocarcinoma 
 
 Junctional adenocarcinoma 
 OR (95% CI) OR (95% CI) OR (95% CI)  OR (95% CI) OR (95% CI) OR (95% CI) 
 Reflux frequency (per week) 
 <1 1-3 >3  No symptoms 1-3 >3 
BMI 20 years ago 
   
 
   <25   1.0 (Ref)   1.0 (Ref)   1.0 (Ref)    1.0 (Ref)   1.0 (Ref)   1.0 (Ref) 
≥25   3.2 (1.9-5.3)     4.0 (1.9-8.1)     6.5 (1.4-29.7)     2.0 (1.4-2.8)     2.3 (1.0-5.1)   11.8 (1.1-131.9)   
BMI maximum  
   
 
   <25   1.0 (Ref)   1.0 (Ref)   1.0 (Ref)    1.0 (Ref)   1.0 (Ref) 
 ≥25   2.1 (1.1-3.9)     2.0 (0.9-4.2)   16.6 (3.2-85.6)     1.4 (1.0-2.1)     2.2 (0.9-5.2)   n.a. 
 Reflux severity (score) 
 0 1-4 >4  No symptoms 1-4 >4 
BMI 20 years ago 
   
 
   <25   1.0 (Ref)   1.0 (Ref)   1.0 (Ref)    1.0 (Ref)   1.0 (Ref)   1.0 (Ref) 
≥25   3.2 (1.9-5.3)     5.1 (2.1-12.2)    3.3 (1.2-9.2)      2.0 (1.4-2.8)     1.8 (0.8-4.1)     4.9 (1.1-21.8)  
BMI maximum  
   
 
   <25   1.0 (Ref)   1.0 (Ref)   1.0 (Ref)    1.0 (Ref)   1.0 (Ref)   1.0 (Ref) 
≥25   2.1 (1.1-3.9)     2.2 (0.9-5.3)   10.0 (2.7-37.1)     1.4 (1.0-2.1)     1.9 (0.8-4.5)   13.6 (2.0-91.3)  
 Reflux duration (years) 
 0 ≤20 >20  No symptoms ≤20 >20 
BMI 20 years ago 
   
 
   <25   1.0 (Ref)   1.0 (Ref)   1.0 (Ref)    1.0 (Ref)   1.0 (Ref)   1.0 (Ref) 
≥25   3.2 (1.9-5.3)     4.7 (2.4-9.2)     1.1 (0.2-6.1)      2.0 (1.4-2.8)     3.0 (1.4-6.8)     2.4 (0.3-19.7)  
BMI maximum  
   
 
   <25   1.0 (Ref)   1.0 (Ref)   1.0 (Ref)    1.0 (Ref)   1.0 (Ref)    
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≥25   2.1 (1.1-3.9)     3.3 (1.5-7.5)     8.9 (1.2-69.1)     1.4 (1.0-2.1)     2.0 (0.9-4.7)   n.a. 
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Table 5. Odds ratios and synergy index (S) of combined exposure for BMI (exposure A) and gastroesophageal reflux (exposure B) with 95% confidence intervals. S = (ORAB – 1) / 
(ORAB� – 1 + ORĀB – 1), A and B denote the presence of and Ā and B� absence of two exposures. Where reference: BMI<25 and not gastroesophageal reflux symptoms, ORAB: 
[BMI≥25 and gastroesophageal reflux symptoms vs. reference], ORAB�: [BMI≥25 and not gastroesophageal reflux symptoms vs. reference], ORĀB: [BMI<25 and gastroesophageal 
reflux symptoms vs. reference]. 
 
Esophageal adenocarcinoma  Junctional adenocarcinoma 
 
ORAB� (95% CI) ORĀB (95% CI) ORAB (95% CI) S
 (95% CI)  ORAB� (95% CI) ORĀB (95% CI) ORAB (95% CI) S
 (95% CI) 
BMI 20 years before interview 
    
 
    Reflux frequency (per week) 
    
 
    1-3 3.3 
(2.0-5.5) 
6.3 
(3.5-11.4) 
19.7 
(10.8-36.0) 
2.4 
(1.3-4.6) 
 2.0 
(1.4-2.9) 
2.1 
(1.3-3.4) 
3.5 
(1.9-6.2) 
1.2 
(0.5-2.9) 
>3 3.1 
(1.9-5.1) 
14.5 
(6.8-31.0) 
64.1 
(21.6-190.4) 
4.0 
(1.2-13.4) 
 2.0 
(1.4-2.9) 
1.8 
(0.8-4.3) 
7.1 
(2.3-22.6) 
3.3 
(0.7-16.4) 
Reflux severity (score) 
    
 
    1-4 3.3 
(2.0-5.5) 
4.2 
(2.2-8.0) 
15.0 
(7.8-28.8) 
2.6 
(1.2-5.3) 
 2.0 
(1.4-2.8) 
2.0 
(1.2-3.3) 
3.0 
(1.6-5.6) 
1.0 
(0.3-2.8) 
>4 3.1 
(1.9-5.2) 
19.0 
(9.7-37.3) 
58.3 
(25.0-136.1) 
2.8 
(1.1-7.2) 
 2.0 
(1.4-2.9) 
2.3 
(1.1-4.9) 
7.0 
(2.9-17.0) 
2.6 
(0.7-9.3) 
Reflux duration (years) 
    
 
    ≤20 3.3 
(2.0-5.4) 
5.3 
(2.9-9.5) 
22.7 
(12.4-41.5) 
3.3 
(1.7-6.3) 
 2.0 
(1.4-2.8) 
1.6 
(1.0-2.7) 
3.7 
(2.1-6.8) 
1.7 
(0.7-4.5) 
>20 3.2 
(1.9-5.4) 
24.3 
(11.1-53.2) 
30.2 
(11.9-76.6) 
1.1 
(0.4-3.4) 
 2.0 
(1.4-2.8) 
4.4 
(1.9-9.8) 
4.5 
(1.7-12.3) 
0.8 
(0.2-3.5) 
BMI maximum as adult 
    
 
    Reflux frequency (per week) 
    
 
    1-3 2.3 
(1.3-4.3) 
7.2 
(3.1-16.5) 
13.8 
(7.2-26.7) 
1.7 
(0.8-3.6) 
 1.4 
(1.0-2.1) 
1.6 
(0.7-3.3) 
3.0 
(1.8-5.0) 
2.0 
(0.5-7.8) 
>3 2.1 
(1.1-3.9) 
5.0 
(1.4-17.9) 
46.2 
(19.5-109.5) 
8.9 
(2.3-34.1) 
 1.4 
(1.0-2.1) 
1.3 
(0.4-4.4) 
4.5 
(1.9-10.6) 
4.7 
(0.4-55.7) 
Reflux severity (score) 
    
 
    1-4 2.2 
(1.2-4.1) 
4.5 
 (1.8-11.6) 
9.7 
(4.9-19.3) 
1.8 
(0.8-4.4) 
 1.4 
(1.0-2.1) 
1.6 
(0.7-3.4) 
2.6 
(1.5-4.4) 
1.6 
(0.4-6.6) 
>4 2.2  
(1.2-4.1) 
10.1 
 (3.6-27.9) 
50.2 
(23.1-108.8) 
4.8 
(1.7-13.2) 
 1.5 
(1.0-2.1) 
1.2 
(0.4-4.1) 
5.4 
(2.6-11.0) 
6.4 
(0.6-71.4) 
Reflux duration (years) 
    
 
    1-20 2.2 
 (1.2-4.1) 
4.7  
(1.9-11.6) 
14.4 
(7.5-27.7) 
2.7 
(1.2-6.1) 
 1.4 
(1.0-2.1) 
1.4 
(0.7-3.0) 
2.6 
(1.6-4.3) 
2.0 
(0.4-8.8) 
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>20 2.2  
(1.2-4.1) 
11.6  
(3.9-34.1) 
42.8 
 (17.8-103.0) 
3.5 
 (1.1-11.1) 
 1.5  
(1.0-2.1) 
1.7  
(0.5-5.9) 
6.6  
(3.0-14.8) 
4.7  
(0.6-35.1) 
 
  
